Redshot FCM, fortified with the advanced Ferric Carboxymallose formulation, designed for administration to both adults and paediatric patients
Cadila Pharmaceuticals announced the launch of a novel iron injection, a next-generation solution for addressing iron deficiency anaemia. The product will be available as Redshot FCM, fortified with the advanced Ferric Carboxymallose formulation, designed for administration to both adults and paediatric patients over one year of age, especially those with oral iron intolerance.
Redshot Injection stands out as an intravenous iron preparation that not only delivers effective amounts of iron but also boasts an exemplary safety profile. With superior tolerability and minimal to zero risk of anaphylaxis, Redshot accelerates the improvement of haemoglobin levels and efficiently replenishes depleted iron stores. Offering heightened tolerability, the intravenous delivery of iron in Redshot facilitates the utilization of high doses in a single administration.
Dr Rajiv I Modi, CMD, Cadila Pharmaceuticals, stated, “This innovation exemplifies our commitment to pharmaceutical excellence, contribution to the safe motherhood initiative, and correction of a very common health condition of iron deficiency anaemia. It not only offers superior tolerability but also presents a transformative approach to replenishing iron stores rapidly and efficiently.”
